The AECC Provides 29.4 Million in Aid for 233 Cancer Research Projects

The Spanish Association Against Cancer (AECC) will allocate 29.4 million euros to 233 cancer research projects. The presentation ceremony of AECC Research Grants 2023 has served to highlight the importance of research in oncology and the objective of increasing the average survival to 70% in 2030. A total of 60 projects, with a value of 5.17 million euros, will be developed in the Community of Madrid.

“The Association provides a response to patients and families in the face of cancer,” said Dr. Pedro Pérez Segura , president of the Technical Committee of the Spanish Association Against Cancer in Madrid, during the inauguration of the event held at the AECC headquarters in Madrid. . The oncologist has highlighted the association’s commitment to “channel social demand into research and give visibility to the work of researchers.”

The vice president of the association’s Scientific Foundation, Dr. Nieves Mijimolle , addressed the goal of the 70% survival challenge by 2030, “promoting research into tumors with low or stagnant survival without neglecting the rest of the research . ” Likewise, she highlighted the awarded projects, which “all have scientific quality. ”

Read more about cancer research projects financing and find the latest economic news from around the world with the Born2Invest mobile app.

Of the total aid, 7.5 million euros are allocated to research projects in childhood cancer

Before proceeding with the delivery of aid, the general director of Research and Teaching of the Community of Madrid, Inmaculada Ibáñez de Cáceres , recognized the work carried out by the AECC. “From the Community of Madrid, we are aware of the need to research cancer because it improves the lives of patients, their families and society.”

The representative of the regional Administration recognized the importance of public-private collaboration in this field, “which is what allows us to move forward . ” Finally, she recalled that the Community has a financial contribution to the foundations, aimed at the “stabilization of professionals who research” in the health field.

With the aim of promoting research in pediatric tumors, the association has joined forces with European entities such as the Foster Consortium

The event coincided with the celebration of International Childhood Cancer Day. Precisely, within this aid package the AECC has allocated 7.5 million euros for 30 projects under development. With the aim of promoting research in pediatric tumors, the association has joined forces with European entities such as the Foster Consortium. Within this consortium, the first clinical trial to be launched is Foster CabOS, whose main objective is to know if the administration of cabozantinib as maintenance treatment after standard treatment of the disease reduces relapses and therefore improves the survival of these patients.

One of the grant projects is a clinical trial to improve the prognosis of acute lymphoblastic leukemia in children under one year of age, the most common pediatric cancer with 1.5 cases per 100,000 inhabitants. A group of researchers from the Interfant network, including Dr. Álvaro Lassaletta, section head of the pediatric oncohematology service at the Niño Jesús Children’s University Hospital in Madrid, and Dr. Blanca Herrero, associate physician at the same center, created the protocol. Interfant-21.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us